A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Myelin Oligodendrocyte Glycoprotein (MOG) Antibody with Reflex to Titer, Serum
Test Code36952
CPT Codes
86362
Includes
If the MOG Antibody screen is positive, then a semi-quantitative titer will be performed at an additional charge (CPT code(s): 86362).
Preferred Specimen
2 mL serum collected in red-top tube (no gel)
Minimum Volume
0.5 mL
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 21 days
Refrigerated: 14 days
Frozen: 21 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Visible particulate matter • Serum separator tube (SST)
Methodology
Cell-based Immunofluorescence Assay
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Sets up 1 day a week.
Report Available
Reports in 2 to 8 days.
Clinical Significance
Neuromyelitis optica (NMO) is an inflammatory disorder predominantly affecting the optic nerves and spinal cord. Limited forms of disease including isolated optic neuritis, brainstem encephalitis and longitudinal extensive transverse myelitis (LETM) or acute disseminated encephalomyelitis (ADEM) have been referred to as NMO spectrum disorder (NMOSD). The majority of individuals with NMO and many with NMOSD have antibodies against aquaporin 4 (AQP4). MOG antibodies have been reported without AQP4 antibodies in individuals with NMO and other non-multiple sclerosis demyelinating diseases. The presence of MOG antibodies in AQP4 antibody negative individuals can help differentiate between multiple sclerosis (MS) and non-MS demyelinating diseases and aid in clinical management decisions.